Cost-effectiveness, not cost containment.
Zbrozek
A S
AS
Department of Internal Medicine, University of Texas Medical Branch at Galveston 77555-0415.
D002945:Cisplatin / Q000009:adverse effects; D003363:Cost Control; D003362:Cost-Benefit Analysis; D004341:Drug Evaluation / Q000191:economics*; D006801:Humans; D008787:Metoclopramide / Q000191:economics / Q000627:therapeutic use; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control; D017294:Ondansetron / Q000191:economics / Q000627:therapeutic use; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control
D017294:Ondansetron; D008787:Metoclopramide; D002945:Cisplatin